Nasdaq atai.

Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market ...

Nasdaq atai. Things To Know About Nasdaq atai.

COMPASS Pathways plc (NASDAQ: CMPS) and Atai Life Sciences N.V. (NASDAQ: ATAI) recently debuted on the stock market, fetching billion dollar valuations, while Seelos Therapeutics, Inc. (NASDAQ ...NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ...Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...

Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) ...

atai Life Sciences (NASDAQ:ATAI) is trading at $1.42, falling from Friday 1’s trading around $1.53 and Friday 25’s close at $1.54. Incannex Healthcare (NASDAQ:IXHL) is trading around $1.34, ...

With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ...Let’s get straight to it: The psychedelic stock market continues to underperform. Taking a look at our Psychedelic Invest Index, we can see that only two companies that trade for a greater than $50 million market cap were up in the month of November: atai Life Sciences (ATAI) & GH Research (GHRS). Wait, there are...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...

On March 30, atai Life Sciences N.V. (NASDAQ: ATAI) reported fourth-quarter and full-year 2021 financial results and R&D progress. The clinical-stage biopharma company also highlighted strategic ...

Alcohol use disorder. Treatment-resistant depression. Opiate withdrawal syndrome. PTSD. Social anxiety in autistic adults. Anxiety with a life-threatening illness. Generalized anxiety disorder ...

NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...Last week, I reported for Psychedelic Spotlight that famed investor Cathie Woods was dipping her toes into the world of psychedelic stocks. On February 8th, ARK’s Genomic Revolution ETF (BATS: ARKG) made an initial investment into the best financed psychedelic medicines company, atai Life Sciences (Nasdaq: ATAI).. I said at the time …Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ...Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …Atai Life Cuts Expenses, Extends Cash Runway. Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Read more here. Rubicon Organics Sales Rise as Premium Brand Grows.3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023.

BEIJING, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ATA Inc. ("ATA" or the "Company", Nasdaq: ATAI), a company focused on providing students with quality educational experiences and services in China and ...Atai Life Sciences N.V. (NASDAQ:ATAI)’s largest hedge fund investor is Israel Englander’s Millennium Management which owns 117,716 shares that are worth $205,000. 11.atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX.NASDAQ Health Care/Life Sciences Compare to Open 1.08 Prior Close 1.04 (11/30/23) 1 Day ATAI 7.21% DJIA 0.30% Russell 2K 1.41% Health Care/Life Sciences 0.38% Overview Per-Share Earnings,...Atai Life Sciences N.V. (NASDAQ:ATAI)’s largest hedge fund investor is Israel Englander’s Millennium Management which owns 117,716 shares that are worth $205,000. 11.

2021 met those requirements, and then some. In fact, in 2021 alone, it is estimated that the psychedelics sector raised more than $2 billion. This was led by atai Life Sciences, who raised more than $400 million. Compass Pathways and MindMed also raised large amounts throughout the year, with Compass closing quarter 3 with almost $300 …

ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock …On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until the 2024 …Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health …Oct 2, 2023 · NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Clinical-stage biotech DemeRx, which is part of Atai Life Sciences’ (NASDAQ: ATAI) portfolio, has completed phase 1 trials for noribogaine and is now planning to launch a phase 2 trial on a ...

ATAI Stock Price | ATAI Life Sciences N.V. Stock Quote (U.S.: Nasdaq ...

Atai Life Sciences N.V. (NASDAQ:ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ:AXSM) Aytu Biopharma, Inc ...

Clinical-stage biopharmaceutical company Atai Life Sciences (NASDAQ:ATAI) declared that it has signed a term loan agreement with Hercules Capital, Inc. for a maximum amount of $175 million.Atai Life Sciences N.V. (NASDAQ:ATAI) AVROBIO, Inc. (NASDAQ:AVRO) Axsome Therapeutics, Inc. (NASDAQ:AXSM) (communicated in its earnings release a potential delay in approval of its major ...Dec 23, 2022 · NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ... ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock analysts, the average 12-month stock price forecast for ATAI stock stock is $13.5, which predicts an increase of 1,116.22%.ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. NVIDIA Corporation Common Stock. ATAI Life Sciences N ... Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...

NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ('atai' or the 'Company'), a global biotech company developing psychedelic and non-psyc... NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a gl...Back to ATAI Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ...Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix.. PsyProtix is a precision psychiatry company focused ...Instagram:https://instagram. firstwesterntrustmid america apartmentbest credit cards for service membersledn.io First, MindMed (Nasdaq: MNMD, NEO: MMED) will present data from their Phase 2a clinical trial attempting to treat Generalized Anxiety Disorder using a large dose of LSD paired with therapy.. For serious MindMed investors, this will be a big moment. While in the short to medium-term stocks can fluctuate wildly, especially speculative biotech …The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023. top movers today stocksasml stock forecast 2025 Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. half dollar prices NASDAQ Health Care/Life Sciences Compare to Open 1.12 Prior Close 1.09 (11/22/23) 1 Day ATAI 0.92% DJIA 0.33% Russell 2K 0.67% Health Care/Life Sciences 0.32% …Company profile for ATAI Life Sciences N.V. including key executives, insider trading, ownership, revenue and average growth rates. View detailed ATAI description & address.